Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so ...

We are excited to welcome the talented team at Regulus to Novartis as we continue to build on our pipeline in renal disease with high unmet medical need.” Farabursen is an investigational ...

Careers at Novartis in Slovenia At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to ...

Albania Algeria Angola Argentina Armenia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bolivia Bosnia and Herzegovina Brazil Bulgaria Burkina Faso ...

An adverse event (or side effect) is any unwanted medical occurrence in a patient who has been given a medicinal product. This can be any unfavourable and unintended sign, symptom, or disease ...

If you are a final year student of undergraduate or postgraduate studies in economics, business, computer and information science, social sciences, logistics, organizational sciences, electrical ...

The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on ...

We must fundamentally reimagine the way we work and create a culture that brings out the best in our people to fulfill our purpose of reimagining medicine to improve and extend people’s lives. We ...

Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Our significant investment in research and development underpins our commitment to ...

Note: Report Adverse events for Novartis Products only. Alternatively, if you are unable to report the side effect electronically you can email your local Novartis Drug Safety Responsible person to: ...

Inclusion criteria For Cohort 1, Patient who meets all the following criteria can be included in this study: 1. Age ≥ 18 years at the time of signing the ICF; 2. Patient with a documented diagnosis of ...